GlassScriptPhysician profile
Edgardo Rivera
NPI 1265561070
$22,584.89
in general payments reported to CMS, 2019-2025
49 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,658 · 2020: $5,029 · 2021: $727 · 2022: $4,908 · 2023: $2,366 · 2024: $764 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,163 · Food and Beverage: $769 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,163.00 |
| Food and Beverage | $769.17 |
| Education | $330.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $5,817.11 | 2019-2025 | Libtayo |
| Janssen Biotech, INC. | $5,383.95 | 2019-2025 | Rybrevant, Erleada |
| Astellas Pharma Global Development | $2,187.50 | 2022 | |
| Glaxosmithkline, LLC. | $2,048.04 | 2020-2021 | |
| Pfizer International LLC | $1,890.00 | 2019 | |
| Pfizer INC. | $419.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $409.44 | 2019-2024 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $384.97 | 2019-2024 | Opdualag |
| Genzyme Corporation | $351.60 | 2019-2021 | |
| Astellas Pharma US INC | $350.08 | 2019-2021 | |
| Amgen INC. | $339.10 | 2019-2023 | Nplate, Vectibix |
| Seagen INC. | $300.35 | 2020-2024 | |
| Celgene Corporation | $265.99 | 2019-2023 | Reblozyl |
| Puma Biotechnology, INC. | $204.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $200.29 | 2019-2024 | Keytruda, Lynparza |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgardo Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.